Amarin slides after EVAPORATE study misses primary endpoint
An investigator-sponsored study of Amarin's Vascepa, called "EVAPORATE," did not hit the primary endpoint for statistical significance on low attenuated plaque, it was reported over the weekend at the American Heart Association's Scientific Sessions 2019 held in Philadelphia, Pennsylvania. The study, which evaluated 80 statin-treated patients via CTCA imaging of plaque at 9 months, did not hit the primary endpoint for statistical significance on low attenuated plaque, although there was a 21% slowing of progression for drug vs. placebo, according to Jefferies analyst Michael Yee. The investigators noted that there were observed differences in plaque parameters at baseline, although low statistical power, no difference in prespecified primary endpoint of change in low attenuated plaque volume, statistically significant differences for four other plaque parameters, beneficial effects on secondary endpoints, and no adverse effect with mineral oil placebo when compared with historical controls, Yee stated in a note to investors regarding the presentation at the AHA meeting. In early afternoon trading, Amarin shares are down $1.63, or 6.8%, to $22.39.